189 related articles for article (PubMed ID: 21222171)
21. [Dutasteride provides chemoprevention].
Werner F
Aktuelle Urol; 2006 Sep; 37(5 Suppl):18. PubMed ID: 23646395
[No Abstract] [Full Text] [Related]
22. Role of 5 alpha-reductase inhibitors in the management of prostate cancer.
Hudak SJ; Hernandez J; Thompson IM
Clin Interv Aging; 2006; 1(4):425-31. PubMed ID: 18046919
[TBL] [Abstract][Full Text] [Related]
23. A review of phase III clinical trials of prostate cancer chemoprevention.
Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
[TBL] [Abstract][Full Text] [Related]
24. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.
Svatek RS; Lotan Y
Cancer Prev Res (Phila); 2011 Feb; 4(2):277-83. PubMed ID: 21163937
[TBL] [Abstract][Full Text] [Related]
25. Dutasteride and prostate cancer.
Garattini S; Bertele' V
N Engl J Med; 2010 Aug; 363(8):794; author reply 794-6. PubMed ID: 20842790
[No Abstract] [Full Text] [Related]
26. Prostate cancer: A closer look at the initial results from the REDUCE trial.
Gann PH
Nat Rev Urol; 2010 Oct; 7(10):535-7. PubMed ID: 20930862
[No Abstract] [Full Text] [Related]
27. [Prostate cancer. Current and practice-relevant news from urology in 2011].
Wirth M; Zastrow S
Urologe A; 2011 Sep; 50 Suppl 1():173-5. PubMed ID: 21842194
[TBL] [Abstract][Full Text] [Related]
28. [Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer].
Schulman C
Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S35-42. PubMed ID: 15651489
[TBL] [Abstract][Full Text] [Related]
29. Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.
Andriole GL; Bostwick DG; Gomella LG; Marberger M; Montorsi F; Tammela TL; Tindall DJ; Fowler IL; Garges HP; Wilson TH; Castro R
Urology; 2014 Aug; 84(2):393-9. PubMed ID: 24916669
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
van Leeuwen PJ; Kölble K; Huland H; Hambrock T; Barentsz J; Schröder FH
Eur Urol; 2011 Feb; 59(2):183-90. PubMed ID: 21130560
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.
Akaza H; Kanetake H; Tsukamoto T; Miyanaga N; Sakai H; Masumori N; Nakatsu H; Sagiyama K; Sakamoto S; Endo Y; Yamanouchi T;
Jpn J Clin Oncol; 2011 Mar; 41(3):417-23. PubMed ID: 21123311
[TBL] [Abstract][Full Text] [Related]
32. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
33. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
Schmidt LJ; Tindall DJ
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):32-8. PubMed ID: 20883781
[TBL] [Abstract][Full Text] [Related]
34. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention of prostate cancer.
Stephenson AJ; Abouassaly R; Klein EA
Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515
[TBL] [Abstract][Full Text] [Related]
36. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
37. Risk adapted chemoprevention for prostate cancer: an option?
Schmitz-Dräger BJ; Schöffski O; Marberger M; Sahin S; Schmid HP
Recent Results Cancer Res; 2014; 202():79-91. PubMed ID: 24531781
[TBL] [Abstract][Full Text] [Related]
38. Effect of dutasteride on the risk of prostate cancer.
Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
[TBL] [Abstract][Full Text] [Related]
39. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
Azzouni F; Mohler J
Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
[TBL] [Abstract][Full Text] [Related]
40. What's wrong with chemoprevention of prostate cancer?
Justman S
Am J Bioeth; 2011 Dec; 11(12):21-5. PubMed ID: 22146025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
